Skip to main content
Caplight Logo









CorneaGen

CorneaGen

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://corneagen.com/

Last Round

Series B

Oct 7, 2019

Total Funding Raised

$47M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

CorneaGen is a medical device and biotechnology company that provides corneal transplant tissue, surgical instruments, and innovative therapeutic solutions to improve outcomes for patients with ocular diseases.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Non-AI

Keywords

corneal transplantprocessed corneal tissueeye bankendothelial keratoplastycorneal surgeryophthalmic surgical devicesregenerative medicinecorneal tissue bankocular tissuesurgical instrumentscorneal implantsdonor tissueophthalmology supplieseye surgery tools

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CorneaGen Comparables

Compare CorneaGen with similar companies based on industry and business-model similarity.

CorneaGen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Brightstar Therapeutics
80%
Eversight
76%
KeraNatural
76%

CorneaGen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 7, 2019
Series AOct 18, 2016

Key People

Founding team and executive leadership

Bernardino Iliakis

President CEO, Board Member

Executive Team

Annie Thompson

Chief Financial Officer

Executive Team

CorneaGen Investors

Notable investors and investment history

CorneaGen investors
InvestorRounds
Petrichor Healthcare Capital ManagementSeries B
Flying L PartnersSeries A, Series B
Falcon VisionSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 33% MoM, reaching 6.3K.

  • Oct 7, 2019

    $37M round led by Petrichor Healthcare Capital Management and Flying L Partners.

CorneaGen Filings

Explore SEC and related filing metadata, where available.

CorneaGen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about CorneaGen's valuation, stock price, and market status.

Is CorneaGen a public or private company?

CorneaGen is a private company.

What is the current stock price of CorneaGen?

CorneaGen is a private company with no public stock price. No recent secondary market data is available.

How much is CorneaGen worth (valuation)?

Valuation information for CorneaGen is not publicly available.

Can I buy CorneaGen stock?

CorneaGen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was CorneaGen's last funding round?

CorneaGen's most recent funding round was Series B on October 7, 2019.

Who are the main investors in CorneaGen?

Key investors in CorneaGen include Petrichor Healthcare Capital Management, Flying L Partners.

Will CorneaGen IPO soon?

No public IPO plans have been announced for CorneaGen.

How can I track CorneaGen secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CorneaGen's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range122
Year Founded2016
Last FundingOct 7, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?